Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 20/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 20/20 | 0.67 |
| ▸ | ADRA1B | P35368 | 20/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7233190 | 0.84 | ADRA1D (0.55) | ADRA1DADRA1AADRA1B | |
| SCHEMBL7225199 | 0.84 | ADRA1D (0.56) | ADRA1DADRA1AADRA1B | |
| SCHEMBL7233750 | 0.78 | ADRA1A (0.56) | ADRA1DADRA1AADRA1B | |
| SCHEMBL7225964 | 0.77 | ADRA1D (0.67) | ADRA1DADRA1AADRA1B | |
| SCHEMBL7226013 | 0.76 | ADRA1A (0.66) | ADRA1DADRA1AADRA1B | |
| SCHEMBL7226776 | 0.76 | ADRA1A (0.60) | ADRA1DADRA1AADRA1B | |
| SCHEMBL7213199 | 0.76 | ADRA1A (0.63) | ADRA1DADRA1AADRA1B | |
| SCHEMBL7218275 | 0.74 | ADRA1D (0.60) | ADRA1DADRA1AADRA1B | |
| SCHEMBL7249029 | 0.74 | ADRA1D (0.51) | ADRA1DADRA1AADRA1B | |
| SCHEMBL7233930 | 0.74 | ADRA1D (0.68) | ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212062-A1 | Morpholinone and morpholine derivatives and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-11-13 | — | — | US | disclosed |
| US-6531471-B2 | Antagonists for human alpha 1a receptors; lowering intraocular pressure; inhibiting cholesterol synthesis; relaxing lower urinary tract tissue; treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia, etc. | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-03-11 | — | — | US | disclosed |
| US-20020068737-A1 | Morpholinone and morpholine derivatives and uses thereof | SYNAPTIC PHARAMCEUTICAL CORPORATION | 2002-06-06 | — | — | US | disclosed |
| US-6362182-B1 | HYPOTENSIVE AGENTS; ANTICHOLESTEROL AGENTS; BENIGN PROSTATIC HYPERTROPIC | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-03-26 | — | — | US | disclosed |
| EP-1140876-A1 | MORPHOLINONE AND MORPHOLINE DERIVATIVES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6218390-B1 | FOR LOWERING INTRAOCULAR PRESSURE, INHIBITING CHOLESTEROL SYNTHESIS, RELAXING LOWER URINARY TRACT TISSUE, THERAPY OF BENIGN PROSTATIC HYPERPLASIA, IMPOTENCY, CARDIAC ARRHYTHMIA, SYMPATHETIC MEDIATED PAIN, MIGRAINE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-04-17 | — | — | US | disclosed |
| WO-2000035891-A1 | MORPHOLINONE AND MORPHOLINE DERIVATIVES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068737-A1 | Morpholinone and morpholine derivatives and uses thereof | ADRA1D, ADRA1A, ADRB1 | ADRA1D 1/4885ADRA1A 2/4885ADRA1B 7/4885 |
| US-20030212062-A1 | Morpholinone and morpholine derivatives and uses thereof | ADRA1D, ADRA1A, ADRB1 | ADRA1D 1/4885ADRA1A 2/4885ADRA1B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.